2015
DOI: 10.1126/scitranslmed.aac5380
|View full text |Cite
|
Sign up to set email alerts
|

DEL-1 restrains osteoclastogenesis and inhibits inflammatory bone loss in nonhuman primates

Abstract: DEL-1 is an endothelial cell-secreted protein that regulates LFA-1-integrin–dependent leukocyte recruitment and inflammation in various tissues. Here we identified a novel regulatory mechanism of DEL-1 in osteoclast biology. Specifically, we showed that DEL-1 is expressed by human and mouse osteoclasts and regulates their differentiation and resorptive function. Mechanistically, DEL-1 inhibited the expression of NFATc1, a master regulator of osteoclastogenesis, in a Mac-1-integrin–dependent manner. In vivo mec… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

11
126
4

Year Published

2016
2016
2024
2024

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 94 publications
(141 citation statements)
references
References 43 publications
11
126
4
Order By: Relevance
“…Since Del-1 blocks LFA-1 binding to its ligand ICAM-1 and prevents neutrophil transmigration [50], it could be administered to inlamed tissues, to reduce neutrophil recruitment, and to reduce inlammation. In fact, this is exactly what was found in a model of periodontitis with nonhuman primates [75]. Local administration of Del-1 also prevented inlammatory bone loss [75].…”
Section: Therapeutic Approachessupporting
confidence: 67%
See 1 more Smart Citation
“…Since Del-1 blocks LFA-1 binding to its ligand ICAM-1 and prevents neutrophil transmigration [50], it could be administered to inlamed tissues, to reduce neutrophil recruitment, and to reduce inlammation. In fact, this is exactly what was found in a model of periodontitis with nonhuman primates [75]. Local administration of Del-1 also prevented inlammatory bone loss [75].…”
Section: Therapeutic Approachessupporting
confidence: 67%
“…In fact, this is exactly what was found in a model of periodontitis with nonhuman primates [75]. Local administration of Del-1 also prevented inlammatory bone loss [75]. Preclinical studies for the use of Del-1 are now underway.…”
Section: Therapeutic Approachessupporting
confidence: 52%
“…Because B and plasma cells are a major source of RANKL in the bone-resorptive lesions of chronic periodontitis [86], the abundance of B-lineage cells in LAD-I periodontitis might further contribute to inflammatory bone loss, secondarily to the dysregulated IL-17 response. Other secondary causes for bone loss in LAD-I periodontitis might be the deficiency of CD18 in osteoclasts, since Mac-1 (CD11b/CD18) is a negative regulator of osteoclastogenesis [87,88]. However, it should be noted that periodontal bone loss is arrested once teeth are removed or lost in LAD-I patients, who moreover have not been reported to have skeletal bone deficit.…”
Section: Concepts Derived From the Study Of Rare Monogenic Diseasesmentioning
confidence: 99%
“…Del-1−Fc generation has been previously described (30). An RGE point mutant of Del-1−Fc, in which Glu (E) was substituted for Asp (D) in the RGD motif of the second EGF repeat (Del-1[RGE]-Fc), was constructed by site-directed mutagenesis (QuickChange II mutagenesis kit; Agilent).…”
Section: Cell Cycle Analysis Of Lt-hscs From Edil3mentioning
confidence: 99%
“…An RGE point mutant of Del-1−Fc, in which Glu (E) was substituted for Asp (D) in the RGD motif of the second EGF repeat (Del-1[RGE]-Fc), was constructed by site-directed mutagenesis (QuickChange II mutagenesis kit; Agilent). Expression and purification were performed as described (30).…”
Section: Cell Cycle Analysis Of Lt-hscs From Edil3mentioning
confidence: 99%